Market Overview

Sosei Subsidiary Heptares Announces Strategic Drug Discovery Collaboration with Pfizer


Sosei Group Corporation (OTC: SOLTF) today announces that its
wholly-owned subsidiary, Heptares Therapeutics has entered into a
strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to
research and develop potential new medicines directed at up to 10 G
protein-coupled receptor (GPCR) targets across multiple therapeutic

Heptares will use its proprietary GPCR structure-guided platform to help
deliver stabilised GPCRs (StaR® proteins), high-resolution
crystal structures and other technologies to support the discovery of
potential novel agents directed to the GPCR targets selected by Pfizer.
Pfizer will be responsible for developing and commercialising any
potential therapeutic agents (small molecules or biologics derived from
StaR antigens) for each target and will have

See full press release

Posted-In: News Contracts Press Releases


Related Articles (PFE + SOLTF)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

China Digital TV Announnces Tongda Ventures Terminated Restructuring Offer

Teva, Takeda Establish Partnership in Japan; Teva to Own 51% Stake, Takeda to Own 49% Stake